Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854604 | 0.74 | PARP1 (0.61) | HRH3PARP1 | |
| SCHEMBL853849 | 0.74 | PARP1 (0.56) | HRH3KCNH2PARP1MEN1KMT2A | |
| SCHEMBL854066 | 0.73 | HRH1 (0.48) | HRH3KCNH2PARP1 | |
| SCHEMBL854970 | 0.71 | PARP1 (0.54) | PARP1 | |
| SCHEMBL854735 | 0.71 | PARP1 (0.69) | HRH3KCNH2PARP1 | |
| Hydrochloric Acid SCHEMBL854655 | 0.70 | PARP1 (0.53) | PARP1 | |
| SCHEMBL854151 | 0.69 | PARP1 (0.52) | HRH3PARP1KMT2A | |
| SCHEMBL3310173 | 0.69 | JAK2 (0.52) | HRH3KCNH2MPO | |
| SCHEMBL30029262 | 0.68 | PARP1 (0.70) | PARP1 | |
| SCHEMBL23302885 | 0.68 | PARP1 (0.72) | TNKSPARP1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | HRH3 2671/4885KCNH2 4080/4885TNKS 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.